Asiaticoside for Treating Overweight/Obesity
ConditionOverweight , Obesity
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorShanghai Zhongshan Hospital
About this trial
Centella asiatica is a traditional herbal medicine widely used in China and Southeast Asia for treating various conditions. Preclinical studies have shown that madecassic acid glycosides, including asiaticoside and madecassoside, can significantly reduce body weight gain, adipose tissue mass, and serum triglyceride levels in high-fat diet-induced obese mice. These compounds also improve hepatic steatosis and insulin resistance. This exploratory, interventional study aims to evaluate the clinical efficacy of orally administered asiaticoside tablets in adults with overweight or obesity.
Eligibility criteria
Qualifiers
Adults aged 18 years or older, male or female.
Overweight or obesity, defined as a body mass index (BMI) of 24.0-45.0 kg/m².
Able and willing to provide written informed consent.
Disqualifiers
Active pulmonary tuberculosis, malignant tumors, human immunodeficiency virus (HIV) infection, or other severe infectious or immunocompromising conditions.
Severe liver injury (AST or ALT > 3 times the upper limit of normal) or severe renal dysfunction/end-stage renal disease (eGFR < 30 mL/min/1.73 m²).
Severe cardiovascular diseases, including angina pectoris, myocardial infarction, or stroke within the past 6 months.
Severe gastrointestinal disorders, or a history of gastrointestinal surgery within the past year.
Trial design
Treatments tested in this trial
- Asiaticoside tablets
Treatment groups
30 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov